vTv completes enrollment in Phase III of RAGE antagonist for AD

vTv Therapeutics LLC (NASDAQ:VTVT) completed enrollment of about 800 patients with mild Alzheimer’s disease in the Phase III STEADFAST trial of azeliragon (TTP488). The double-blind, placebo-controlled, North American trial is evaluating the change from baseline in AD Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating Sum of Boxes (CDR-SB) scores at 18 months. Secondary endpoints include changes in MRI brain volumetric measures, FDG-PET imaging, Neuropsychiatric Inventory (NPI), Mini-Mental State Examination (MMSE) and AD Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL). vTv plans to report data from the trial next year...